Abstract
Acute idiopathic thrombocytopenic purpura (AITP) in children is generally a benign disease with a high frequency of spontaneous remission. Nevertheless the debate over treating or not is still open, because of the high risk of hemorrhage as long as the platelet count remains below 20 x 109/l. We have retrospectively evaluated 120 pediatric cases from our center, receiving different treatments at diagnosis: no treatment (76); IVIG: 400 mg/kg/d for 5 days (28); continuous oral PDN: 1-1.5 mg/kg/d for at least two weeks (16). No patients had been previously treated for AITP. Follow-up is up to fifty months. We found no significant differences as to the percentage of responses among the three groups. We conclude that waiting without treatment is safe and appropriate in most cases; whether the hemorrhagic risk suggests treatment, standard dose continuous oral PDN and IVIG may be equally effective, but IVIG may achieve a significantly faster rise in the platelet count. The timing of treatment and the cost/benefit ratio are discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 457-461 |
| Number of pages | 5 |
| Journal | Annali dell'Istituto Superiore di Sanita |
| Volume | 34 |
| Issue number | 4 |
| Publication status | Published - 1998 |
Fingerprint
Keywords
- Immune thrombocytopenic purpura
- Immunoglobulins
- Steroid
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
Cite this
Treatment of acute idiopathic thrombocytopenic purpura in children. A retrospective evaluation of 120 cases. / Baronci, Carlo; Petrone, Angelamaria; Miano, Crescenzo; Lombardi, Alessandra; Caniglia, Maurizio; Russo, Lidia Angiolina; Luciani, Matteo; Pinto, Rita Maria; Rana, Ippolita; Caruso, Roberta; De Rossi, Giulio.
In: Annali dell'Istituto Superiore di Sanita, Vol. 34, No. 4, 1998, p. 457-461.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of acute idiopathic thrombocytopenic purpura in children. A retrospective evaluation of 120 cases
AU - Baronci, Carlo
AU - Petrone, Angelamaria
AU - Miano, Crescenzo
AU - Lombardi, Alessandra
AU - Caniglia, Maurizio
AU - Russo, Lidia Angiolina
AU - Luciani, Matteo
AU - Pinto, Rita Maria
AU - Rana, Ippolita
AU - Caruso, Roberta
AU - De Rossi, Giulio
PY - 1998
Y1 - 1998
N2 - Acute idiopathic thrombocytopenic purpura (AITP) in children is generally a benign disease with a high frequency of spontaneous remission. Nevertheless the debate over treating or not is still open, because of the high risk of hemorrhage as long as the platelet count remains below 20 x 109/l. We have retrospectively evaluated 120 pediatric cases from our center, receiving different treatments at diagnosis: no treatment (76); IVIG: 400 mg/kg/d for 5 days (28); continuous oral PDN: 1-1.5 mg/kg/d for at least two weeks (16). No patients had been previously treated for AITP. Follow-up is up to fifty months. We found no significant differences as to the percentage of responses among the three groups. We conclude that waiting without treatment is safe and appropriate in most cases; whether the hemorrhagic risk suggests treatment, standard dose continuous oral PDN and IVIG may be equally effective, but IVIG may achieve a significantly faster rise in the platelet count. The timing of treatment and the cost/benefit ratio are discussed.
AB - Acute idiopathic thrombocytopenic purpura (AITP) in children is generally a benign disease with a high frequency of spontaneous remission. Nevertheless the debate over treating or not is still open, because of the high risk of hemorrhage as long as the platelet count remains below 20 x 109/l. We have retrospectively evaluated 120 pediatric cases from our center, receiving different treatments at diagnosis: no treatment (76); IVIG: 400 mg/kg/d for 5 days (28); continuous oral PDN: 1-1.5 mg/kg/d for at least two weeks (16). No patients had been previously treated for AITP. Follow-up is up to fifty months. We found no significant differences as to the percentage of responses among the three groups. We conclude that waiting without treatment is safe and appropriate in most cases; whether the hemorrhagic risk suggests treatment, standard dose continuous oral PDN and IVIG may be equally effective, but IVIG may achieve a significantly faster rise in the platelet count. The timing of treatment and the cost/benefit ratio are discussed.
KW - Immune thrombocytopenic purpura
KW - Immunoglobulins
KW - Steroid
UR - http://www.scopus.com/inward/record.url?scp=0032424821&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032424821&partnerID=8YFLogxK
M3 - Article
VL - 34
SP - 457
EP - 461
JO - Annali dell'Istituto Superiore di Sanita
JF - Annali dell'Istituto Superiore di Sanita
SN - 0021-2571
IS - 4
ER -